Indian Pharma Gets USFDA Approval To Market Tablets To Treat Osteoporosis In The US

The approval for Aurobindo Pharma’s Raloxifene Hydrochloride tablets is for strength of 60 mg that is therapeutically equivalent to Evista, 60 mg of Eli Lilly.

The US Food and Drug Administration (USFDA) has approved Indian drug firm, Aurobindo Pharma, to manufacture and market its generic version of Eli Lilly's Evista tablets used to treat and prevent osteoporosis in postmenopausal women.

The approval by the USFDA for Raloxifene Hydrochloride tablets is for strength of 60 mg, which is bio and therapeutically equivalent to the reference listed drug product (RLD) Evista, 60 mg of Eli Lilly, the company said in a statement.

Benefits of a New Osteoporosis Drug Enhanced by 'Unsung' Cells
A scientifically overlooked group of cells are likely crucial to the process of bone loss.

The product has an estimated market size of USD 404 million for the 12 months ended June 2015, the company added, citing IMS data. This is the 45th Abbreviated New Drug Application (ANDA) to be approved out of Unit VII formulation facility in Hyderabad for manufacturing oral non-antibiotic products.

Aurobindo now has a total of 210 ANDA approvals, 182 final ones, including 9 from Aurolife Pharma LLC and 28 tentative approvals from US FDA, it added.

Source-PTI

Aurobindo Pharma Get FDA Nod for Marketing Nafcillin Injections in US
Aurobindo Pharma revealed that it has received an approval from the US Food and Drug Administration to market Nafcillin injections

Aurobindo Pharma Receives FDA Approval to Market Generic Narcolepsy Drug
Aurobindo Pharma revealed that it has received approval from the US Food and Drug Administration to manufacture modafinil tablets in the US.

Risky Osteoporosis Drug may be Suspended
An osteoporosis drug, apparently risky, including the risk of heart attacks, may now be suspended by a committee in Europe

MEDINDIA

Search Medindia

Indian Pharma Gets USFDA Approval To Market Tablets To Treat Osteoporosis In The US

The approval for Aurobindo Pharma’s Raloxifene Hydrochloride tablets is for strength of 60 mg that is therapeutically equivalent to Evista, 60 mg of Eli Lilly.